<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36924785</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Imprinted hybrid immunity against XBB reinfection.</ArticleTitle><Pagination><StartPage>764</StartPage><EndPage>765</EndPage><MedlinePgn>764-765</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(23)00138-X</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(23)00138-X</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boyton</LastName><ForeName>Rosemary J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College London, London W12 0NN, UK; Lung Division, Royal Brompton Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK. Electronic address: r.boyton@imperial.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altmann</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Immunology and Inflammation, Imperial College London, London W12 0NN, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/V036939/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Lancet Infect Dis. 2023 Jul;23(7):799-805. doi: 10.1016/S1473-3099(23)00060-9</RefSource><PMID Version="1">36924786</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000084063" MajorTopicYN="Y">Reinfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056704" MajorTopicYN="Y">Adaptive Immunity</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>RJB and DMA are supported by UK Research and Innovation/Medical Research Council (MR/S019553/1, MR/R02622X/1, MR/V036939/1, and MR/W020610/1); the National Institute for Health and Care Research (NIHR) Imperial Biomedical Research Centre: Institute for Translational Medicine and Therapeutics; the Cystic Fibrosis Trust Strategic Research Centre (2019SRC015); NIHR Efficiency and Mechanism Evaluation Fast Track (NIHR134607); NIHR Long COVID (COV-LT2-0027); Innovate UK (SBRI 10008614); and the Horizon 2020 Marie Sk&#x142;odowska-Curie Innovative Training Network European Training Network (860325).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>16</Day><Hour>20</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36924785</ArticleId><ArticleId IdType="pmc">PMC10010702</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00138-X</ArticleId><ArticleId IdType="pii">S1473-3099(23)00138-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altmann DM. The COVID-19 immunology masterclass enters its fourth year. Nat Immunol. 2023;24:201&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">36604546</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186:279. 86.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9747694</ArticleId><ArticleId IdType="pubmed">36580913</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Jiang S, Jiang S, et al. Neutralization of SARS-CoV-2 BQ.1.1 and XBB.1.5 by breakthrough infection sera from previous and current waves in China. bioRxiv. 2023 doi: 10.1101/2023.02.07.527406. published online Feb 18. (preprint).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.02.07.527406</ArticleId><ArticleId IdType="pmc">PMC10300020</ArticleId><ArticleId IdType="pubmed">37369648</ArticleId></ArticleIdList></Reference><Reference><Citation>Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397:1057&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7972310</ArticleId><ArticleId IdType="pubmed">33640038</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, Pade C, Gibbons JM, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021;372:1418&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8168614</ArticleId><ArticleId IdType="pubmed">33931567</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, Gibbons JM, Pade C, et al. Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science. 2022;375:183&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10186585</ArticleId><ArticleId IdType="pubmed">34855510</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C, Chiew CJ, Pang D, et al. Protective immunity of natural SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study. Lancet Infect Dis. 2023 doi: 10.1016/S1473-3099(23)00060-9. published online March 13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00060-9</ArticleId><ArticleId IdType="pmc">PMC10306341</ArticleId><ArticleId IdType="pubmed">36924786</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, Pade C, Gibbons JM, et al. Immune boosting by B.1.1.529 (omicron) depends on previous SARS-CoV-2 exposure. Science. 2022;377</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9210451</ArticleId><ArticleId IdType="pubmed">35699621</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Jian F, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent omicron RBD evolution. Nature. 2023;614:521&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9931576</ArticleId><ArticleId IdType="pubmed">36535326</ArticleId></ArticleIdList></Reference><Reference><Citation>Edridge AWD, Kaczorowska J, Hoste ACR, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020;26:1691&#x2013;1693.</Citation><ArticleIdList><ArticleId IdType="pubmed">32929268</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasrado N, Collier AY, Miller J, et al. Waning immunity against XBB.1.5 following bivalent mRNA boosters. bioRxiv. 2023 doi: 10.1101/2023.01.22.525079. published online Jan 23. (preprint).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.01.22.525079</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Boyton RJ. COVID-19 vaccination: the road ahead. Science. 2022;375:1127&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">35271316</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>